In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma.

@article{Ocio2010InVA,
  title={In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma.},
  author={Enrique Mar{\'i}a Ocio and David Vilanova and Peter W Atadja and Patricia Maiso and Edvan de Queiroz Cruso{\'e} and Diego Fern{\'a}ndez-L{\'a}zaro and Mercedes Garayoa and Laura San-Segundo and Teresa Hern{\'a}ndez-Iglesias and Enrique de Alava and Wenlin Shao and Yung-mae Yao and Atanasio Pandiella and Jes{\'u}s F San-Miguel},
  journal={Haematologica},
  year={2010},
  volume={95 5},
  pages={794-803}
}
BACKGROUND Combinations of drug treatments based on bortezomib or lenalidomide plus steroids have resulted in very high response rates in multiple myeloma. However, most patients still relapse, indicating the need for novel combination partners to increase duration of response or to treat relapsed disease. We explored the antimyeloma activity of triple combinations of these well-established schemes with panobinostat, a novel deacetylase inhibitor with a multi-targeted profile. DESIGN AND… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS